WALTHAM, Mass., March 14, 2022 – Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that Daniel Grau, CEO and President, will present at the upcoming Guggenheim Targeted Protein Degradation Day at 2:00PM – 2:30PM on Wednesday, March 16, 2022. The format of the day will consist of analyst-led panel discussions with companies and experts on a series of topics in targeted protein degradation including the current status and future outlook for therapeutics across oncology, inflammation, neurology, and other potential areas.
About Avilar Therapeutics
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATACmediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-inclass extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA. For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com